Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study

Fig. 2

Flow diagram exhibiting the methods applied to identify objects to evaluate survival of pembrolizumab plus enzalutamide (PE) versus pembrolizumab alone (PA) in selected men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us